2023
Left Ventricular Ejection Fraction and the Future of Heart Failure Phenotyping
Dimond M, Ibrahim N, Fiuzat M, McMurray J, Lindenfeld J, Ahmad T, Bozkurt B, Bristow M, Butler J, Carson P, Felker G, Jessup M, Murillo J, Kondo T, Solomon S, Abraham W, O'Connor C, Psotka M. Left Ventricular Ejection Fraction and the Future of Heart Failure Phenotyping. JACC Heart Failure 2023, 12: 451-460. PMID: 38099892, DOI: 10.1016/j.jchf.2023.11.005.Peer-Reviewed Original Research
2022
Medicare Coverage and Out-of-Pocket Costs of Quadruple Drug Therapy for Heart Failure
Faridi K, Dayoub E, Ross J, Dhruva S, Ahmad T, Desai N. Medicare Coverage and Out-of-Pocket Costs of Quadruple Drug Therapy for Heart Failure. Journal Of The American College Of Cardiology 2022, 79: 2516-2525. PMID: 35738713, DOI: 10.1016/j.jacc.2022.04.031.Peer-Reviewed Original ResearchConceptsSodium-glucose cotransporter 2 inhibitorsAngiotensin receptor neprilysin inhibitorQuadruple therapyOOP costsMedicare coveragePocket costsAngiotensin-converting enzyme inhibitorPrior authorizationAngiotensin receptor blockersQuadruple drug therapyCotransporter 2 inhibitorsMineralocorticoid receptor antagonistsReduced ejection fractionDrug plansReceptor blockersEjection fractionHeart failureDrug therapyReceptor antagonistPrescription drug plansMedicare patientsEnzyme inhibitorsTherapyRegimensMedication pricesHeart Failure Spending Function: An Investment Framework for Sequencing and Intensification of Guideline-Directed Medical Therapies
Allen LA, Teerlink JR, Gottlieb SS, Ahmad T, Lam CSP, Psotka MA. Heart Failure Spending Function: An Investment Framework for Sequencing and Intensification of Guideline-Directed Medical Therapies. Circulation Heart Failure 2022, 15: e008594. PMID: 35000432, DOI: 10.1161/circheartfailure.121.008594.Peer-Reviewed Original ResearchConceptsGuideline-directed medical therapyMedical therapyReduced ejection fractionHealth care delivery researchAdverse eventsCardiac benefitsSerum creatinineBlood pressureEjection fractionHeart failureRoutine carePatient burdenHeart rateNew therapiesPatient harmHigh dosesPatientsPsychosocial domainsPocket costsTherapeutic opportunitiesClinical useTherapyNew drugsPhysiological domainsSpending function
2020
A Novel Treatment for a Rare Cause of Cardiogenic Shock
Chowdhury M, Azari BM, Desai NR, Ahmad T. A Novel Treatment for a Rare Cause of Cardiogenic Shock. JACC Case Reports 2020, 2: 1461-1465. PMID: 34316997, PMCID: PMC8302098, DOI: 10.1016/j.jaccas.2020.02.004.Peer-Reviewed Original Research
2017
ADVANCED ANALYTICS PREDICTED OUTCOMES, IDENTIFIED CLINICALLY DISTINCT SUBGROUPS, AND DETECTED HETEROGENEITY IN RESPONSE TO THERAPY IN A COHORT OF MORE THAN 40,000 HEART FAILURE PATIENTS
Ahmad T, Rao P, Lund L, Warrier P, Rohit G, Desai N. ADVANCED ANALYTICS PREDICTED OUTCOMES, IDENTIFIED CLINICALLY DISTINCT SUBGROUPS, AND DETECTED HETEROGENEITY IN RESPONSE TO THERAPY IN A COHORT OF MORE THAN 40,000 HEART FAILURE PATIENTS. Journal Of The American College Of Cardiology 2017, 69: 2558. DOI: 10.1016/s0735-1097(17)35947-8.Peer-Reviewed Original Research